OpenEvidence’s $250M Series D round at a $12B valuation marks a defining moment for AI-led healthcare platforms. Co-led by Thrive Capital and DST Global, the round doubles the company’s valuation since October, underlining how quickly investor confidence is accelerating in clinically embedded AI.
What sets OpenEvidence apart is not just capital raised, but real-world scale. With 18 million monthly clinical consultations and over $100M in revenue, the platform has moved beyond experimentation into operational dependence for healthcare professionals. This traction positions OpenEvidence as infrastructure, not just software.
The backing roster GV, Sequoia, NVIDIA, Kleiner Perkins, Blackstone, BOND, Craft Ventures, and Mayo Clinic reflects a rare convergence of tech, capital markets, and medical credibility. That mix signals long-term intent: building AI systems that clinicians trust, regulators can support, and enterprises can scale globally.
From a strategic lens, the funding shifts OpenEvidence’s priorities from rapid adoption to execution at scale. This includes deeper investment in clinical accuracy, governance, data security, and specialised talent, alongside expansion into new healthcare systems and geographies. Organisationally, it also means evolving people strategy balancing AI research excellence with healthcare domain leadership.
As healthcare AI matures, valuation is increasingly tied to outcomes, reliability, and integration into everyday clinical decision-making. OpenEvidence’s latest raise suggests the market believes it can meet that bar. The next phase will test whether the company can transform growth momentum into long-term system-level impact.
